Tonix Pharmaceuticals (TNXP) stock falls as the company misses Street forecasts on Q4 2024 revenue miss ahead of an FDA ...

August 15, 2025, is the FDA PDUFA goal date for TNX-102 SL for the management of fibromyalgia; If approved, TNX-102 SL would ...

Clade I, the culprit in the current 2025 version of global epidemic mpox, is highly transmissible and is spreading within ...

Tonix Pharmaceuticals shares are trading higher by 22.5% during Monday's session. The company announced that the FDA will not ...

The FDA previously granted Fast Track designation to TNX-102 SL for the management of fibromyalgia in 2024, a designation intended to expedite FDA review of important new drugs to treat serious ...

Tonix Pharmaceuticals Holding Corp.’s TNXP share price has surged by 32.48%, which has investors questioning if this is right time to sell.

Tonix Pharmaceuticals (TNXP) announced that the U.S. Food and Drug Administration will not require an Advisory Committee meeting to discuss the ...

Investing.com -- Shares of Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) surged 18% after the company announced that the U.S. Food and Drug Administration (FDA) will not require an Advisory ...

Tonix Pharmaceuticals (NASDAQ: TNXP) , a biopharmaceutical company with marketed products and a robust development pipeline, announced that the FDA w ...

Reports Q4 revenue $2.6M, consensus $3.35M.”With commercial preparations underway, we believe we are well positioned to launch TNX-102 SL for ...